UGT1A9, UGT2B7, and MRP2 Genotypes Can Predict Mycophenolic Acid Pharmacokinetic Variability in Pediatric Kidney Transplant Recipients

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Therapeutic Drug Monitoring

• Publication date

  2012-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/FTD.0b013e3182708f84PMID 23131697PMCID PMC3498586
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring.

  2011cited by this paper
• Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.

  2011cited by this paper
• The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease

  2011cited by this paper
• Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients

  2011cited by this paper
• Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.

  2011cited by this paper
• Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation.

  2010cited by this paper
• Population Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid Following Administration of Mycophenolate Mofetil in De Novo Pediatric Renal‐Transplant Patients

  2010cited by this paper
• UGT Genotype May Contribute to Adverse Events Following Medication With Mycophenolate Mofetil in Pediatric Kidney Transplant Recipients

  2009cited by this paper
• Mechanistic basis of using body size and maturation to predict clearance in humans.

  2009cited by this paper
• Increased Mycophenolic Acid Exposure in Stable Kidney Transplant Recipients on Tacrolimus as Compared With Those on Sirolimus: Implications for Pharmacokinetics

  2009cited by this paper
• Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors

  2008cited by this paper
• Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers.

  2008cited by this paper
• Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients

  2007cited by this paper
• The Impact of UGT1A8, UGT1A9, and UGT2B7 Genetic Polymorphisms on the Pharmacokinetic Profile of Mycophenolic Acid After a Single Oral Dose in Healthy Volunteers

  2007cited by this paper
• C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.

  2007influential reference
• Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid

  2006influential reference
• Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients

  2006cited by this paper
• ROLE OF MRP2 IN THE HEPATIC DISPOSITION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE METABOLITES: EFFECT OF CYCLOSPORINE

  2006cited by this paper
• Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation

  2006cited by this paper
• Mycophenolate Mofetil in Pediatric Renal Transplantation

  2005cited by this paper
• Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance‐Associated Protein 2

  2005cited by this paper
• A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil

  2005cited by this paper
• Influence of Co‐Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation

  2005cited by this paper
• Comparison of a New QMS?? Zonisamide Assay* on the Hitachi?? 911/912 Systems to the Hitachi 717?? System**: 20

  2005cited by this paper
• The impact of uridine diphosphate–glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single‐nucleotide polymorphisms T—275A and C—2152T on early mycophenolic acid dose‐interval exposure in de novo renal allograft recipients

  2005cited by this paper
• Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting Periods

  2005cited by this paper
• IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM

  2005cited by this paper
• Recursive partitioning analysis of complex disease pharmacogenetic studies. I. Motivation and overview.

  2005cited by this paper
• The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants.

  2004cited by this paper
• An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes.

  2004cited by this paper
• Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver.

  2004cited by this paper
• Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10-hydroxycamptothecin and Flavopiridol Anticancer Drugs

  2003cited by this paper
• Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies

  2003cited by this paper
• Twelve‐Month Evaluation of the Clinical Pharmacokinetics of Total and Free Mycophenolic Acid and Its Glucuronide Metabolites in Renal Allograft Recipients on Low Dose Tacrolimus in Combination with Mycophenolate Mofetil

  2003cited by this paper
• Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition.

  2002cited by this paper
• Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid.

  2000cited by this paper
• Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression

  2000cited by this paper
• Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus.

  1999cited by this paper
• Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure.

  1998cited by this paper
• Clinical Pharmacokinetics of Mycophenolate Mofetil

  1998cited by this paper
• The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation

  1998cited by this paper
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.

  1995cited by this paper
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection

  1995cited by this paper
• PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION

  1995cited by this paper
• Simplified calculation of body-surface area.

  1987cited by this paper
• Simplified Calculation of Body-Surface Area

  1987cited by this paper
• A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

  1976cited by this paper

• Trends in Precision Medicine and Pharmacogenetics as an Adjuvant in Establishing a Correct Immunosuppressive Therapy for Kidney Transplant: An Up-to-Date Historical Overview

  2025cites this paper
• Influence of UDP-Glucuronosyltransferase Polymorphisms on Mycophenolic Acid Metabolism in Renal Transplant Patients.

  2024cites this paper
• Androgenrezeptor-gerichtete Therapien – klinisch relevante Interaktionen vermeiden

  2024cites this paper
• An Integrated Sampling Strategy for Therapeutic Mycophenolic Acid Monitoring in Lung Transplant Recipients.

  2024cites this paper
• Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis–A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study)

  2024cites this paper
• Influence of genetic polymorphisms on pharmacokinetics and treatment response of mycophenolic acid: a scoping review.

  2024cites this paper
• Cannabis Pharmacogenomics: A Path to Personalized Medicine

  2023cites this paper
• Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives

  2023cites this paper
• Use of Pharmacogenetics to Optimize Immunosuppressant Therapy in Kidney-Transplanted Patients

  2022cites this paper
• Precision Medicine: Towards Individualized Dosing in Pediatric Rheumatology.

  2022cites this paper
• [Pharmacokinetic study of mycophenolic acid in pediatric kidney transplantation].

  2022cites this paper
• Genetic polymorphisms in metabolic enzymes and transporters have no impact on mycophenolic acid pharmacokinetics in adult kidney transplant patients co‐treated with tacrolimus: A population analysis

  2021cites this paper
• CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients

  2021cites this paper
• Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

  2021cites this paper
• Recent Advances in Therapeutic Drug Monitoring of Voriconazole, Mycophenolic Acid, and Vancomycin: A Literature Review of Pediatric Studies

  2021cites this paper
• Post-transplant Medication Challenges

  2021cites this paper
• Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients

  2021influential citation
• The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children

  2020cites this paper
• PGPM_A_231329 13..27

  2020cites this paper
• Pharmacogenomics of Immunosuppressants

  2020cites this paper
• Impacto del polimorfismo MRP2 24ct en el trasplante renal en tratamiento con ácido micofenólico: farmacocinética y repercusión clínica

  2019cites this paper
• Kidney Transplantation in Children

  2019cites this paper
• Acute rejection in kidney transplantation and the evaluation of associated polymorphisms (SNPs): the importance of sample size

  2019cites this paper
• Mycophenolic Acid and Its Pharmacokinetic Drug‐Drug Interactions in Humans: Review of the Evidence and Clinical Implications

  2019cites this paper
• The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling

  2018cites this paper
• Renal Drug Transporters and Drug Interactions

  2017cites this paper
• Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance

  2017cites this paper
• Relationship between UGT1A9 gene polymorphisms, efficacy, and safety of propofol in induced abortions amongst Chinese population: a population-based study

  2017cites this paper
• Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients’ and donors’ ABCC2 gene variants, and their interactions

  2017cites this paper
• Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial

  2017cites this paper
• Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis

  2017cites this paper
• Pharmacogénétique des immunosuppresseurs : état des connaissances et des pratiques – recommandations du Réseau national de pharmacogénétique (RNPGx)

  2017cites this paper
• Mycophenolate mofetil‐related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugs

  2017cites this paper
• Pharmacogenetics of immunosuppressants: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics (RNPGx).

  2017cites this paper
• Use of Glucuronidated Mycophenolic Acid Levels for Therapeutic Monitoring in Pediatric Lupus Nephritis Patients

  2016cites this paper
• Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites

  2016cites this paper
• Chapter 12 – Pharmacology and Drug Therapy: Nonbiologic Therapies

  2016cites this paper
• Evolution in Pediatric Pharmacology: Microdosing, metabolism, and membrane transporters

  2016influential citation
• Physiological scaling factors and mechanistic models for prediction of renal clearance from in vitro data

  2016influential citation
• Developmental changes of MPA exposure in children

  2016cites this paper
• The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy

  2016cites this paper
• Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy

  2016cites this paper
• Intracellular concentrations of immunosuppressants

  2016cites this paper
• Therapeutic drug monitoring in pediatric renal transplantation

  2015cites this paper
• Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation

  2015cites this paper
• The effects of drugs with immunosuppressive or immunomodulatory activities on xenobiotics-metabolizing enzymes expression in primary human hepatocytes.

  2015cites this paper
• What is the intrapatient variability of mycophenolic acid trough levels?

  2015cites this paper
• Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group

  2015cites this paper
• Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics

  2015influential citation
• Découverte de nouveaux marqueurs pharmacogénomiques de la maladie du greffon contre l'hôte en transplantation de cellules souches hématopoïétiques

  2014cites this paper
• Study to identify the associations between polymorphisms in pharmacogenetic loci, mycophenolic acid precursors (mofetil or sodium) and clinical outcomes in renal transplant recipients using array based exome SNP sequencing

  2014cites this paper
• Pharmacogenetics and immunosuppressive drugs in solid organ transplantation

  2014cites this paper
• Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus.

  2014cites this paper
• Recipient uridine 5'-diphospho-glucuronosyltransferase UGT1A9 c.98T>C variant determines transplanted kidney filtration rate.

  2014cites this paper
• Species differences in sinusoidal and canalicular efflux transport of mycophenolic acid 7-O-glucuronide in sandwich-cultured hepatocytes

  2014influential citation
• Sorafenib Metabolism Is Significantly Altered in the Liver Tumor Tissue of Hepatocellular Carcinoma Patient

  2014cites this paper
• Mycophenolic Acid Pharmacokinetics in Lung Transplant Recipients With Cystic Fibrosis

  2014cites this paper
• Similar MPA Exposure on Modified Release and Regular Tacrolimus

  2014cites this paper
• Impact of ABC transporters on secondary fungal metabolites as remedies or toxins

  2014cites this paper
• Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy.

  2013cites this paper
• Lung transplantation: Transplant outcomes, graft dysfunction

  year unknowncites this paper